In Phase 3 of clinical trials, Pfizer said it found that its vaccine, known as BNT162b2, was 95 percent effective in developing immunity to the CCP virus.
The drug company has submitted a request for emergency approval from the FDA, which could allow it to use the vaccine in high-risk populations in the United States.
FDA attorney Alan Minsk said it could be available by the end of the year, but he’s cautiously optimistic.